Cargando…

Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients

Background and Aims: The drug resistance of hepatitis B virus (HBV) originates from mutations within HBV reverse transcriptase (RT) region during the prolonged antiviral therapy. So far, the characteristics of how these mutations distribute and evolve in the process of therapy have not been clarifie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Ya, Wu, Songhang, Hu, Yuhai, Chen, Tianbin, Zeng, Yongbin, Liu, Can, Ou, Qishui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605321/ https://www.ncbi.nlm.nih.gov/pubmed/33124952 http://dx.doi.org/10.1080/22221751.2020.1835446

Ejemplares similares

Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma
por: Fu, Ya, et al.
Publicado: (2022)

Characterization and Clinical Significance of Natural Variability in Hepatitis B Virus Reverse Transcriptase in Treatment-Naive Chinese Patients by Sanger Sequencing and Next-Generation Sequencing
por: Fu, Ya, et al.
Publicado: (2019)

Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach
por: Xun, Zhen, et al.
Publicado: (2022)

A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population
por: Wu, Wennan, et al.
Publicado: (2023)

IFIT3 Is Increased in Serum from Patients with Chronic Hepatitis B Virus (HBV) Infection and Promotes the Anti-HBV Effect of Interferon Alpha via JAK-STAT2 In Vitro
por: Xu, Siyi, et al.
Publicado: (2022)

Toll‐like receptors, long non‐coding RNA NEAT1, and RIG‐I expression are associated with HBeAg‐positive chronic hepatitis B patients in the active phase
por: Zeng, Yongbin, et al.
Publicado: (2019)

Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function
por: Xun, Zhen, et al.
Publicado: (2021)

Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022)

Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients
por: Lai, Xiaoqin, et al.
Publicado: (2022)

The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone
por: Lin, Sheng, et al.
Publicado: (2020)

Emerging role of mitochondria in response to HBV infection
por: Lin, Caorui, et al.
Publicado: (2022)

Drug-Related Mutational Patterns in Hepatitis B Virus (HBV) Reverse Transcriptase Proteins From Iranian Treatment-Naïve Chronic HBV Patients
por: Mahabadi, Mostafa, et al.
Publicado: (2013)

Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention
por: Jones, Scott A, et al.
Publicado: (2013)

Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2018)

Nomogram Model for Prediction of SARS-CoV-2 Breakthrough Infection in Fujian: A Case–Control Real-World Study
por: Chen, Tianbin, et al.
Publicado: (2022)

Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B
por: Mahabadi, Mostafa, et al.
Publicado: (2016)

Corrigendum: Hepatitis B Virus (HBV) Infection and Re-activation During Nucleos(t)ide Reverse Transcriptase Inhibitor–Sparing Antiretroviral Therapy in a High–HBV Endemicity Setting
por: Abdullahi, Adam, et al.
Publicado: (2019)

Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection
por: Zhang, Xiaoman, et al.
Publicado: (2019)

Endogenous reverse transcriptase and RNase H-mediated antiviral mechanism in embryonic stem cells
por: Wu, Junyu, et al.
Publicado: (2021)

AUSTRALIA ANTIGEN, CORONAVIRUS, AND REVERSE TRANSCRIPTASE IN VIRAL HEPATITIS
por: Sirtori, Carlo
Publicado: (1971)

Establishment of Real Time Allele Specific Locked Nucleic Acid Quantitative PCR for Detection of HBV YIDD (ATT) Mutation and Evaluation of Its Application
por: Zeng, Yongbin, et al.
Publicado: (2014)

Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients
por: Sultana, Camelia, et al.
Publicado: (2022)

Pre-Existing Mutations in Reverse Transcriptase of Hepatitis B Virus in Treatment-Naive Chinese Patients with Chronic Hepatitis B
por: Xu, Jie, et al.
Publicado: (2015)

Effect of lipemia and bilirubinemia on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a five-year analysis
por: Pattery, T, et al.
Publicado: (2010)

Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression
por: Choi, Yu-Min, et al.
Publicado: (2018)

Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan
por: Ababneh, Nidaa A., et al.
Publicado: (2019)

Diverse regulatory manners of human telomerase reverse transcriptase
por: Jie, Meng-Meng, et al.
Publicado: (2019)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

Differential Binding of Tenofovir and Adefovir to Reverse Transcriptase of Hepatitis B Virus
por: van Hemert, Formijn J., et al.
Publicado: (2014)

A reverse transcriptase ribozyme
por: Samanta, Biswajit, et al.
Publicado: (2017)

The GG Genotype of Telomerase Reverse Transcriptase at Genetic Locus rs2736100 Is Associated with Human Atherosclerosis Risk in the Han Chinese Population
por: Feng, Lei, et al.
Publicado: (2014)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
por: Molès, Jean-Pierre, et al.
Publicado: (2009)

HIV-1 Subtype and Reverse Transcriptase Genotype: Role for Geographical Location and Founder Effects
por: Ojesina, Akinyemi I, et al.
Publicado: (2006)

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda
por: Goodall, R. L., et al.
Publicado: (2014)

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance
por: Wainberg, Mark A.
Publicado: (2012)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Hepatitis B Virus–Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma
por: Sze, Karen Man‐Fong, et al.
Publicado: (2020)

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
por: Liu, Ya-Yun, et al.
Publicado: (2018)

Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis
por: Rose, Ronald E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ps8a4vl31rm5fqjl8q8cn0hfls